Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07397325 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Oct 5, 2026 → Feb 5, 2027
See other at-risk trials from Applied Biology, Inc.

Record History

  1. Recruitment openedv5 Show 4 more changesShow less
    • Primary completion pushed from Oct 5, 2026 to Feb 5, 2027
    • Study completion pushed from Dec 7, 2026 to Mar 5, 2027
    • Start date changed from estimate of Apr 16, 2026 to May 16, 2026
    • Site details revised at 2 of 2 sites
  2. Re-verified, no change to tracked fieldsv4
  3. Start date: Mar 16, 2026 to Apr 16, 2026
    • Study sites: 1 to 2
    v3
  4. Interventions: DA-020 (Drug), DA-020 and Hyperforin (1.5%) (Drug), Placebo (Drug) to DA-020 (Drug), DA-020 and Hyperforin (Drug), Placebo (Drug)v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Clinical Study of DA-020 as a Treatment for Chemotherapy Induced Alopecia
Trial Details
NCT Number NCT07397325
Lead Sponsor Applied Biology, Inc.
Collaborators: Daniel Alain, Inc., Follea International Limited
Conditions
(from sponsor)		 Chemotherapy Induced Alopecia, Chemotherapy Side Effects
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov